The Latin America, Middle East and Africa Fusion Biopsy Market is expected to witness market growth of 12.3% CAGR during the forecast period (2020-2026).
The growing incidence of prostate cancer, increasing adoption of multiparametric MRI in prostate cancer treatment and care along with greater specificity of fusion biopsy are some of the factors that are expected to drive the targeted MR/Ultrasound biopsy system demand in the coming years. According to several studies, the success rate of prostate biopsy combined with traditional core biopsy is about 33%, while the MR/US fusion biopsy has the success rate ranging from 58-70%. Thus, the need for a repeat biopsy is eliminated by fusion biopsy and therefore minimizes additional healthcare costs and patient discomfort.
At times, it is hard to detect prostate cancer and fusion biopsy is very beneficial in this. The Fusion Biopsy System Market is likely to grow globally at a significant CAGR in the forecast period because of the fact that the scope, product types, and applications of these products are continuously increasing across the globe. A Fusion biopsy system combines MRI ultrasound along with biopsy system for a better view. Fusion biopsy is also termed as fusion guided biopsy. Moreover, biopsy infers taking the tissue sample from the body then examines the report and detect it in the best possible manner. When test previously done in case of any prostrate related problems and if that test shows an anomaly in certain areas of the sample; then doctors recommend for biopsy.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
By Route
By Country
Companies Profiled
Unique Offerings from the Publisher
The growing incidence of prostate cancer, increasing adoption of multiparametric MRI in prostate cancer treatment and care along with greater specificity of fusion biopsy are some of the factors that are expected to drive the targeted MR/Ultrasound biopsy system demand in the coming years. According to several studies, the success rate of prostate biopsy combined with traditional core biopsy is about 33%, while the MR/US fusion biopsy has the success rate ranging from 58-70%. Thus, the need for a repeat biopsy is eliminated by fusion biopsy and therefore minimizes additional healthcare costs and patient discomfort.
At times, it is hard to detect prostate cancer and fusion biopsy is very beneficial in this. The Fusion Biopsy System Market is likely to grow globally at a significant CAGR in the forecast period because of the fact that the scope, product types, and applications of these products are continuously increasing across the globe. A Fusion biopsy system combines MRI ultrasound along with biopsy system for a better view. Fusion biopsy is also termed as fusion guided biopsy. Moreover, biopsy infers taking the tissue sample from the body then examines the report and detect it in the best possible manner. When test previously done in case of any prostrate related problems and if that test shows an anomaly in certain areas of the sample; then doctors recommend for biopsy.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
- Diagnostic centers
- Hospitals
- Ambulatory care centers
By Route
- Transperineal
- Transrectal
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Fusion Biopsy Market by End Uses
Chapter 5. LAMEA Fusion Biopsy Market by Route
Chapter 6. LAMEA Fusion Biopsy Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Methodology
LOADING...
